Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $14.54

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average recommendation of “Hold” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $14.5357.

A number of brokerages have issued reports on PSNL. TD Cowen reissued a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Craig Hallum cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research report on Monday, August 24th. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target on the stock. in a research report on Monday, July 20th. Finally, Zacks Research cut shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st.

Personalis Stock Up 2.2%

Shares of PSNL opened at $17.20 on Wednesday. The company has a 50-day moving average price of $14.55 and a two-hundred day moving average price of $10.28. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -15.78 and a beta of 2.31. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. Equities research analysts expect that Personalis will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This represents a 20.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 256,233 shares of company stock valued at $3,568,236 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd increased its stake in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after buying an additional 1,655 shares during the last quarter. Royal Bank of Canada lifted its position in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares in the last quarter. Howland Capital Management LLC lifted its position in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after buying an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.